Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

ocular hypertension or glaucoma in both eyes
currently treated with brimonidine
requires IOP-lowering therapy in both eyes

Exclusion criteria

uncontrolled systemic disease
known allergy or sensitivity to brimonidine

Treatment and study plan

Brimonidine

Drug

Primary outcomes

lowering of intraocular pressure

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 2005
Primary completion: 2006
Study completion: 2006
First posted: Sep 15, 2005
Registry last updated: May 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed